European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary EmbolismJuly 29, 2014 8:38 am | News | Comments
Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway.
Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research...
Bristol-Myers Squibb Company today announced that, following discussions with the FDA, the...
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® and Sunvepra® Dual RegimenJuly 7, 2014 8:19 am | News | Comments
Bristol-Myers Squibb Company has announced that the Japanese Ministry of Health, Labor and...
BMS Issues Voluntary Nationwide Recall of COUMADIN® for Injection Due to Presence of Particulate MatterJune 30, 2014 1:40 pm | News | Comments
Bristol-Myers Squibb Company is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.
Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early. Bristol-Myers said patients treated with nivolumab lived longer than patients who received only chemotherapy.
Bristol-Myers Squibb Company has announced that the U.S. Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found the patent covering Baraclude (entecavir), U.S. patent 5,206,244 invalid.
Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India.
Actavis has filed an Abbreviated New Drug Application with the FDA seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza.
Bristol-Myers Squibb Company and Incyte Corporation announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Bristol-Myers Squibb and AbbVie today announced that the FDA has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies
Shares of Bristol-Myers Squibb slumped Thursday after the drugmaker reported disappointing clinical trial data for an experimental cancer treatment.
BMS and Celldex Therapeutics to Evaluate the Combination of Investigational Immunotherapies Nivolumab and VarlilumabMay 14, 2014 8:46 am | News | Comments
Bristol-Myers Squib and Celldex Therapeutics have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study.
Bristol-Myers Squibb Company today announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company, effective July 1, 2014.
Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierian's issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175 million, with the potential for additional development and regulatory milestone payments totaling $550 million, along with future royalties on net sales.
Bristol-Myers Squibb Co. reported a 54 percent jump in first-quarter profit, as cost cutting and a gain from selling most of its diabetes business outweighed a slight dip in sales.
Bristol-Myers Squibb Company announced today the submission of a new drug application (NDA) on April 4, 2014 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz®, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective.
Five Prime Therapeutics and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform.
Bristol-Myers Squibb Company and Pfizer announced that the FDA approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
People who take Januvia, Byetta or certain other widely prescribed medicines for diabetes can breathe a little easier — U.S. and European regulators have found no compelling evidence of a link between these drugs and pancreas problems or pancreatic cancer.
Shares of Bristol-Myers Squibb Co. rose Monday after a BMO Capital Markets analyst upgraded the stock, saying Bristol-Myers has a promising group of cancer drug.
Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.
AstraZeneca today announced that it has completed the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
Bristol-Myers Squibb Co. reported a 21.5 percent drop in its fourth-quarter profit despite higher drug sales, because the year-ago results had a $411 million tax benefit from writing off a failed experimental medicine.
AstraZeneca and Bristol-Myers Squibb today announced that Xigduo™ (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorization by the European Commission for the treatment of type 2 diabetes in the European Union (EU).
The U.S. Food and Drug Administration has approved a new diabetes drug from Bristol-Myers Squibb and AstraZeneca that uses a novel approach to reduce blood sugar. Farxiga is a once-a-day tablet designed to help diabetes patients eliminate excess sugar via their urine. That differs from older...
Bristol-Myers Squibb Company and Pfizer have announced that the FDA has accepted for review a Supplemental New Drug Application (sNDA) for ELIQUIS ® (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE.
AstraZeneca PLC will buy out Bristol-Myers Squibb Co.'s stake in their partnership to develop and sell diabetes drugs in a deal worth $4.1 billion — seizing an opportunity to serve the projected explosion of patients suffering from the disease.
A panel of federal health advisers has overwhelmingly backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety. The Food and Drug Administration panel voted 13-1 on Thursday in favor of the drug from...
- Page 1